
05/10/2021
We’re honored to announce $20.5M in funding led by Mayfield Fund to develop the first no-needle, no-blood platform for disease monitoring.
We’ve sought to solve a holy grail problem - extracting data from blood without breaking the skin. Our approach has the power to unlock an all-new way to understand and manage chronic disease, with our first target in glucose monitoring for diabetes.
Read more from TechCrunch:
GraphWear, a company pursuing needle-free approaches to glucose monitoring, has closed a $20.5 million Series B round. This Series B round is a vote of confidence by investors in GraphWear’s approach: to monitor key metrics in the body, like glucose, without breaking the skin at all. GraphWear Tec...